CONMED Corporation — 2014 Q1 Form 10-Q Summary
Business context and reporting period
CONMED is a medical technology company focused on surgical devices and equipment for minimally invasive procedures and monitoring. Its principal product lines are orthopedic surgery, general surgery, and surgical visualization. This unaudited Form 10-Q covers the three months ended March 31, 2014, compared with the three months ended March 31, 2013.
International sales represented approximately 52.0% of first-quarter 2014 net sales. The company continued operational and administrative restructuring, including manufacturing consolidation and production transfers to Mexico.
Key financial metrics
| Metric | Q1 2013 | Q1 2014 | Change |
|---|---|---|---|
| Net sales | $187.0 million | $181.9 million | Down 2.7% |
| Gross profit | $102.7 million | $102.6 million | Down 0.1% |
| Gross margin | 54.9% | 56.4% | Up 1.5 percentage points |
| Income from operations | $15.9 million | $17.3 million | Up 9.1% |
| Operating margin | 8.5% | 9.5% | Up 1.0 percentage point |
| Net income | $10.5 million | $8.6 million | Down 17.8% |
| Diluted EPS | $0.37 | $0.31 | Down $0.06 |
| Operating cash flow | $5.5 million | $17.0 million | Up $11.6 million |
Net sales were affected by lower general surgery and surgical visualization sales, partly offset by growth in orthopedic surgery. Capital equipment sales declined 9.4% to $35.5 million, while single-use product sales declined 0.9% to $146.4 million.
Research and development expense increased to $6.9 million from $5.7 million. Selling and administrative expense declined to $73.8 million from $77.7 million. Other expense increased to $3.2 million from $1.8 million, primarily because of patent-related legal and settlement costs and consulting fees.
The effective tax rate increased to 45.6% from 26.3%, including a $2.3 million non-cash write-off of New York State deferred tax assets following tax legislation that reduced the applicable manufacturing tax rate to essentially zero. Interest expense was $1.5 million, compared with $1.4 million, while the weighted average borrowing rate declined to 2.36% from 2.43%.
Cash and cash equivalents were $56.3 million at March 31, 2014, compared with $54.4 million at December 31, 2013. Net working capital was $266.7 million. Capital expenditures were $4.1 million in the quarter, and management expected approximately $20.0 million of capital expenditures for full-year 2014.
Total debt consisted primarily of $235.0 million outstanding under the $350.0 million revolving senior credit facility and a $7.6 million mortgage note. Available revolver capacity was $107.9 million, including approximately $7.1 million reserved for letters of credit. The company was in compliance with its debt covenants at March 31, 2014.
Material changes versus the prior comparable period
- Sales declined 2.7%, driven by a 17.8% decline in surgical visualization and a 4.9% decline in general surgery. Orthopedic surgery sales increased 0.9%.
- Gross margin improved to 56.4%, primarily due to lower costs from completed restructuring initiatives.
- Operating income and operating margin improved despite lower revenue.
- Net income declined because of the substantially higher effective tax rate and increased other expense.
- Operating cash flow improved substantially, partly because the company made no pension contribution in 2014 and benefited from working-capital changes.
- Share repurchases totaled $16.9 million, compared with $25.7 million in the prior-year quarter. The company repurchased 402,416 shares during the quarter and had $37.4 million remaining under its authorized program.
- The quarterly dividend increased to $0.20 per share from $0.15 per share.
Guidance, outlook, risks, contingencies, and unusual items
Management stated that cash on hand, operating cash flow, and available borrowing capacity should be sufficient to meet anticipated working-capital needs, debt service, capital expenditures, and share repurchases. Management was cautiously optimistic about improving economic conditions but noted that sales had declined in 2013 and in the first quarter of 2014.
Additional restructuring costs were estimated at approximately $7.5 million to $8.5 million for the remainder of 2014. The company had a $1.7 million restructuring accrual at March 31, 2014. The Centennial, Colorado manufacturing consolidation was expected to continue over the next 24 months.
Other unusual items included $1.9 million of patent-related legal costs and a $0.9 million settlement accrual, $0.6 million of consulting fees, and the $2.3 million non-cash tax charge. The company also had a contingent obligation under its MTF distribution agreement; $33.3 million remained accrued at March 31, 2014, including $16.7 million due within the next fiscal year and the remainder due in 2016.
The FDA issued a Warning Letter in January 2014 concerning observations from a 2013 inspection of the Centennial facility. CONMED was undertaking corrective actions. Although remediation costs were not expected to be material, the filing noted potential risks of recalls, additional regulatory actions, consent decrees, or fines.
The company remains exposed to foreign-exchange and interest-rate volatility, litigation, product liability, regulatory compliance, competition, healthcare cost-containment pressures, inventory obsolescence, availability of allograft tissue, and the execution and expected savings from restructuring activities. Management did not expect pending claims or investigations to have a material adverse effect, but provided no assurance that future matters would not do so.
Important facts for investors to verify
- Whether the decline in general surgery and surgical visualization sales persists and whether orthopedic growth continues.
- Whether restructuring produces the expected margin benefits and whether the projected $7.5 million to $8.5 million of additional 2014 costs changes.
- The effect of the elevated tax rate and whether future tax rates normalize after the New York tax-law change.
- Progress on FDA corrective actions at the Centennial facility and any resulting recalls, fines, or other regulatory measures.
- Cash requirements associated with the remaining $33.3 million MTF contingent obligation.
- Revolver availability, covenant compliance, interest-rate exposure, and the company’s ability to fund repurchases, dividends, capital expenditures, and debt service.
- Potential costs and outcomes of patent, product-liability, environmental, and other legal proceedings.
- Execution of the share repurchase and dividend policies given the company’s leverage and cash-flow requirements.